Carolyn Nguyen

Carolyn Nguyen is an associate in the firm’s Life Sciences and Technology group. Carolyn advises domestic and international clients on mergers and acquisitions, venture capital financings, joint ventures, spin-offs, and other strategic transactions. Carolyn has significant experience representing venture capital funds and private equity funds in connection with their investments in the life sciences and technology industries. Carolyn was previously a judicial extern for Presiding Justice Robert M. Mallano of the California Court of Appeal, Second Appellate District, Division 1.

Carolyn’s representative transactions include:

Venture Financing

Company-Side

• Lykos Therapeutics, Inc. (f/k/a MAPS Public Benefit Corporation) in its Series A Preferred Stock financing of more than $100 million
• CARGO Therapeutics, Inc. in its $200 million Series A Preferred Stock financing
• Wellinks in its $25 million Series C Preferred Stock financing
• Nuvig Therapeutics, Inc. in its $47 million Series A Preferred Stock financing
• Pyramid Biosciences Inc. in its Series B Preferred Stock financing
• Confluent, Inc. in its $125 million Series D Preferred Stock financing*
• Imperative Care, Inc. in its $85 million Series C Preferred Stock financing*
• Compound Labs, Inc. its $25 million Series A Preferred Stock financing*
• Unbabel, Inc. in its $60 million Series C Preferred Stock financing*
• Returnly, Inc. in its $19 million Series B Preferred Stock financing*
• RideCell, Inc. in its $60 million Series B Preferred Stock financing*
• UpStart Holdings, Inc. in its $50 million Series D Preferred Stock financing*

Investor-Side

• Bain Capital Life Sciences in Areteia Therapeutics, Inc.’s $350 million Series A Preferred Stock financing
• a16z crypto, as lead investor, in Yuga Labs’s $450 million Series Seed Preferred Stock financing
• a16z crypto, as lead investor, in Alchemy Insights, Inc.’s $250 million Series C Preferred Stock financing
• Paradigm Fund in its investment in Succinct Inc.’s Series Seed Preferred Stock financing
• Warburg Pincus, as lead investor, in its investment in Contrast Security, Inc.’s $65 million Series D Preferred Stock financing*
• Warburg Pincus, as lead investor, in its investment in Outset Medical, Inc.’s $60 million Series B Preferred Stock financing*
• Warburg Pincus, as lead investor, in its investment in BriteCore Holdings, Inc.’s $47.5 million Series B Preferred Stock financing*
• Steadfast Capital in its investment in Primer Technologies, Inc.’s $110 million Series C Preferred Stock financing*
• Steadfast Capital in its investment in Talos Trading Inc.’s $40 million Series A Preferred Stock financing*

Mergers and Acquisitions

Buy-Side

• Aurobac Therapeutics SAS in its acquisition of certain assets of ContraFect Corporation
• Ji Xing Pharmaceuticals Hong Kong Limited in its acquisition of certain assets of PhaseBio Pharmaceuticals, Inc.
• Blueprint Medicines Corporation in its acquisition of Lengo Therapeutics, Inc. for up to $465 million
• AbCellera Biologics Corporation in its acquisition of TetraGenetics, Inc.
• Merck Sharpe & Dohme Corp. in its acquisition of Afferent Pharmaceuticals, Inc. for approximately $1.25 billion*
• Brocade Communications Systems, Inc. in its acquisition of Ruckus Wireless, Inc. for approximately $1.2 billion*
• Brocade Communications Systems, Inc. in its acquisition of Stackstorm, Inc.*
• OMERS Private Equity in its acquisition of Golfsmith International*
• Tempur Sealy International Inc. in its acquisition of Interiores 750 S.A. de C.V.*
• The world’s largest equipment rental company in numerous asset acquisitions of rental equipment companies and distributors*

Sell-Side

• Dharma Labs, Inc. in its sale to Ozone Networks, Inc. (f/k/a Open Sea)
• TIMCO Aviation Services, Inc. in its sale to Hong Kong Aircraft Engineering Company Limited for approximately $388.8 million*
• ShoCard, Inc. in its sale to Ping Identity Corporation*
• ARMA Global Corporation in its sale to General Dynamics Corporation*
• Procera Networks, Inc. in its sale to Francisco Partners*

Other Representative Transactions

• Royalty Pharma in its acquisition of a revenue interest and equity stake in ApiJect Holdings, Inc.
• Blackstone Credit in its $1.2 billion financing of Westland Insurance Group Ltd.*
• Blackstone Tactical Opportunities in its investment in Diligent Corporation*
• Achieve Life Sciences, Inc. in its reverse merger with OncoGenex Pharmaceuticals, Inc.*

* Denotes experience prior to joining Goodwin.